Flatiron Health at SABCS 2025
Flatiron is excited to attend and present our research at the 2025 San Antonio Breast Cancer Symposium, showcasing how our real-world data and research capabilities generate real-world insights that answer high priority research questions around treatment effectiveness, biomarker-driven approaches, clinical outcomes, and real-world access.
Get a preview of our SABCS research presence from Catherine Keane, Senior Clinical Director at Flatiron
Flatiron is your trusted partner in delivering oncology evidence to support the evolving research questions across your breast cancer portfolio
970K+
patients with breast cancer
300+
published pieces of breast cancer research
70+
research questions answered with custom data and services
Featured solutions
Panoramic data
Flatiron's foundational real-world data, flexibly designed to meet the needs of biopharma’s evolving research priorities with biomarker depth, scaled outcomes, and longitudinal data across our entire network of 5M+ patients.
Real-world data
Our flexible real-world data configurations are tailored to address the specific needs of your oncology portfolio and now encompass more than 5 million patient journeys, 4 of the largest oncology markets in the world, 22+ tumor types, and multimodal data.
Real-world evidence services
Flatiron’s in-house expertise and flexible engagement models can help you generate the insights and evidence you need to advance your portfolio, from refining target product profiles, to conducting comparative effectiveness studies and supporting regulatory and HTA submissions.
Our research
Flatiron is excited to share our accepted research at this year’s conference.
Personalized acquired CDK4/6i resistance: Associations with baseline characteristics like obesity in real-world (RW) clinical-multiomics data
Spotlight poster presentation
See this research
Poster Spotlight 3
Presentation Date/Time: Wednesday, December 10, 2025, 7:33 AM - 7:36 AM
Location: 302 ABC
connect with a flatiron expert
Director, Scientific Engagement
Connect on Linkedin
Racial/ethnic inequities in access to novel therapies and outcomes in triple negative breast cancer
Spotlight poster presentation
See this research
Poster Spotlight 1
Presentation Date/Time: Wednesday, December 10, 2025, 7:45 AM - 7:48 AM
Location: Hemisfair 3
connect with a flatiron expert
Senior Health Equity Scientist
Connect on Linkedin
Real-world glucagon-like peptide-1 use and association with clinical characteristics, social determinants, and circulating tumor DNA positivity in patients with breast cancer
Spotlight poster presentation
See this research
Poster Spotlight 8
Presentation Date/Time: Thursday, December 11, 2025, 8:03 AM - 8:06 AM
Location: 221 ABC
connect with a flatiron expert
Senior Health Equity Scientist
Connect on Linkedin
Real-world progression-free survival 2 (rwPFS2) and tumor response with CDK4/6is + aromatase inhibitor (AI) in patients (pts) with HR+/HER2– metastatic breast cancer (MBC)
See this research
Poster Session 1: Wednesday, December 10, 2025, 12:30 PM–2:00 PM
connect with a flatiron expert
Aaron Cohen, MD
Head of Research Oncology, Clinical Data
Connect on Linkedin
Real-world treatment patterns and clinical outcomes in patients with emerging estrogen receptor 1 (ESR1)-mutated ER+ metastatic breast cancer in the U.S., 2018-2024
See this research
Poster Session 2: Wednesday, December 10, 2025, 5:00 PM - 6:30 PM
connect with a flatiron expert
James Roose
Senior Research Scientist
Connect on Linkedin
Real-world treatment patterns in 1954 US patients with HER2-negative early breast cancer and germline BRCA mutations (2021–2025)
See this research
Poster Session 2: Wednesday, December 10, 2025, 5:00 PM - 6:30 PM
connect with a flatiron expert
Senior Clinical Director
Connect on Linkedin
Real-world overall survival with palbociclib plus an aromatase inhibitor (AI) in patients with HR+/HER2− metastatic breast cancer (MBC) who are overweight/obese
See this research
Poster Session 2: Wednesday, December 10, 2025, 5:00 PM - 6:30 PM
connect with a flatiron expert
Director, Research Sciences
Connect on Linkedin
Want to learn more about how Flatiron’s Evidence Solutions can support research across your breast cancer portfolio?
Flatiron’s industry-leading oncology solutions unlock global insights in breast cancer research.
Contact us to learn more about Flatiron’s flexible evidence solutions.